Inimmune Corporation, a US-based clinical-stage biotechnology company, announced on Tuesday that it has signed a research collaboration with Boston Children's Hospital (BCH).
The research collaboration is aimed at developing novel and innovative small molecule vaccine adjuvants. An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer-lasting immunity against infections than the vaccine alone.
The Precision Vaccines Program (PVP) at Boston Children's Hospital was awarded a Vaccine Adjuvant Development Program contract (75N93023C00040) from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) that can extend up to five years and USD9m to develop a small molecule TLR7/8 agonist adjuvant that will enhance the effectiveness of flu vaccines.
Ofer Levy, MD, PhD, director of the PVP, said: "The Precision Vaccines Program is dedicated to pioneering the next generation of vaccines tailored to safeguard the most vulnerable among us. We are building a global network to revolutionise vaccine development, and we are excited to collaborate with Inimmune to enhance adjuvants."
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034